Furthermore, pan-HDAC inhibitors have shown therapeutic potential in preclinical models of lung fibrosis (Zhang et al., 2013; Ye et al., 2014; Ota et al., 2015; Rao et al., 2016; Korfei et al., 2018). Here, HDAC9 is linked to pulmonary fibrosis.